Placental malaria (PM) is a deadly syndrome most frequent and severe in first pregnancies.
PM results from accumulation of Plasmodium falciparum-infected erythrocytes (IE) that …

Background Pregnancy-associated malaria (PAM) is a serious consequence of Plasmodium
falciparum-infected erythrocytes sequestration in the placenta through the adhesion to the …

VAR2CSA is the Plasmodium falciparum variant surface antigen that mediates binding of
infected erythrocytes to chondroitin sulfate A (CSA) and their sequestration in intervillous …

Pregnancy-associated malaria (PAM) is characterized by the placental sequestration of
Plasmodium falciparum-infected erythrocytes (IEs) with the ability to bind to chondroitin …

Over 50 million women are exposed to the risk of malaria during pregnancy every year.
Malaria during pregnancy is a leading global cause of maternal morbidity and adverse …

Two vaccines based on Plasmodium falciparum protein VAR2CSA are currently in clinical
evaluation to prevent placental malaria (PM), but a deeper understanding of var2csa …

In areas where Plasmodium falciparum transmission is endemic, clinical immunity against
malaria is progressively acquired during childhood and adults are usually protected against …

Plasmodium falciparum-infected erythrocytes (IE) sequester in the placenta via surface
protein VAR2CSA, which binds chondroitin sulfate A (CSA) expressed on the …

Background Pregnancy-associated malaria (PAM) is a serious consequence of the
adhesion to the placental receptor chondroitin sulfate A (CSA) of Plasmodium falciparum …

Placental malaria (PM) due to Plasmodium falciparum is a major cause of maternal, fetal
and infant mortality, but the mechanisms of pathogenesis and protective immunity are …